The tor pathway: a target for cancer therapy

By M. Bjornsti, P. Houghton. Nature Reviews. Cancer, 2004

1,375 citations recorded by the source corpus.

Subfields: Ecology, Evolution, Behavior and Systematics, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/1de14ff44e8df2086c8d6d303b4e50dcfd05f32f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Ecology, Evolution, Behavior and Systematics

In Molecular Biology

Citations in the corpus

Modelling glandular epithelial cancers in three-dimensional cultures (2005, background): “The effects of AKT activation on morphological disruption, individual cell size and shape are all prevented by rapamycin, a highly specific pharmacological inhibitor of the AKT effector mTO”
Target identification using drug affinity responsive target stability (DARTS) (2009, methodology): “As a test case, we used the human mTOR (mammalian target of rapamycin) protein, which is an important target (23, 24) and had been identified on the basis of its association with the FKBP12-rapamycin complex (see references in ref.”
Systems biology and combination therapy in the quest for clinical efficacy (2006, background): “Inhibition of mTOR is promising as an anticancer strategy, as many proteins lying upstream and downstream of mTOR are deregulated in a human cance”
Potential therapeutic applications of autophagy (2007, background): “Rapamycin is suitable for long-term human use (for example, to prevent renal-transplant rejection) and rapamycin analogues are in Phase III trials for gliomas and advanced renal carcinom”
Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance (2005, background): “Rapamycin, an inhibitor of mTOR, is an approved immunosuppressive drug, and clinical trials with rapamycin analogues RAD-001 and CCI-779 for late-stage carcinomas, such as breast, prostate, melanoma, pancreatic and glioblastoma, are being investigate”
Rapamycin alleviates toxicity of different aggregate-prone proteins. (2006, background): “Rapamycin was approved as an immunosuppressant drug in 1999 and its water-soluble analogues, such as CCI-779 and RAD001, are currently in phase III (CCI-779) and phase II (RAD001) clinical trials for cancer (43,44).”
Cell Death Pathways in Photodynamic Therapy of Cancer (2011, background): “kinase (TOR), which controls cell growth and protein synthesis [111].”
Mechanisms of type-I- and type-II-interferon-mediated signalling (2005, background): “125 ), leading to the de-activation of 4EBP1 and its dissociation from EIF4E, and the initiation of translatio”
Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma (2008, background): “Inhibitors of the mammalian target of rapamycin (mTOR) have received regulatory approval as immunosuppressive agents for the treatment of allograft rejection and as antitumor agents for kidney cancer [6,7].”
Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. (2007, background): “In addition, loss of TSC2 can lead to dysregulation of hypoxia inducible factor-1a and increased angiogenesis, which plays a critical role in tumor progression (10).”
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. (2006, methodology): “majority of cancers contributing to deregulation of proliferation, resistance to apoptosis, and changes in metabolism characteristic of transformed cells (1, 2).”
Upstream and downstream of mTOR. (2004, background): “…not surprising that rapamycin inhibits tumor growth and is currently in phase I–III clinical trails (for reviews, see Mita et al. 2003; Sawyers 2003; Bjornsti and Houghton 2004; Houghton and Huang 2004). mTOR function in synaptic plasticity, memory, and learning The creation and maintenance of…”
Dysregulation of the TSC-mTOR pathway in human disease (2004, background): “Furthermore, mTOR inhibitors have potent growth-inhibitory activity against the development of various types of malignant tumors, indicative of great potential for anticancer treatmen”